Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer.
Gao Y, Ventura-Diaz S, Wang X, He M, Xu Z, Weir A, Zhou HY, Zhang T, van Duijnhoven FH, Han L, Li X, D'Angelo A, Longo V, Liu Z, Teuwen J, Kok M, Beets-Tan R, Horlings HM, Tan T, Mann R. Gao Y, et al. Among authors: van duijnhoven fh. Nat Commun. 2024 Nov 7;15(1):9613. doi: 10.1038/s41467-024-53450-8. Nat Commun. 2024. PMID: 39511143 Free PMC article.
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
Groen EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, Mann RM, van Ramshorst MS, Lips EH, Vrancken Peeters MTFD, van Duijnhoven FH, Wesseling J. Groen EJ, et al. Among authors: van duijnhoven fh, van der noordaa mem, van ramshorst ms. Breast Cancer Res Treat. 2021 Aug;189(1):213-224. doi: 10.1007/s10549-021-06235-2. Epub 2021 May 4. Breast Cancer Res Treat. 2021. PMID: 33945043 Free PMC article.
Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
van Olmen JP, Jacobs CF, Bartels SAL, Loo CE, Sanders J, Vrancken Peeters MTFD, Drukker CA, van Duijnhoven FH, Kok M. van Olmen JP, et al. Among authors: van duijnhoven fh. Breast. 2024 Jun;75:103726. doi: 10.1016/j.breast.2024.103726. Epub 2024 Apr 5. Breast. 2024. PMID: 38599047 Free PMC article.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luykx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, Blank CU, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M. Nederlof I, et al. Among authors: van duijnhoven fh. Nat Med. 2024 Nov;30(11):3223-3235. doi: 10.1038/s41591-024-03249-3. Epub 2024 Sep 16. Nat Med. 2024. PMID: 39284953 Free PMC article. Clinical Trial.
Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.
Alaeikhanehshir S, Voets MM, van Duijnhoven FH, Lips EH, Groen EJ, van Oirsouw MCJ, Hwang SE, Lo JY, Wesseling J, Mann RM, Teuwen J; Grand Challenge PRECISION Consortium Steering Group. Alaeikhanehshir S, et al. Among authors: van oirsouw mcj, van duijnhoven fh. Cancer Imaging. 2024 Apr 5;24(1):48. doi: 10.1186/s40644-024-00691-x. Cancer Imaging. 2024. PMID: 38576031 Free PMC article.
Clinical impact of MRI-detected additional lesions in breast cancer patients with neoadjuvant systemic therapy at the Netherlands cancer institute.
van Loevezijn AA, Winter-Warnars HAO, Hernández GS, de Bloeme CM, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: van duijnhoven fh. Breast Cancer Res Treat. 2023 Feb;198(1):131-141. doi: 10.1007/s10549-022-06840-9. Epub 2023 Jan 2. Breast Cancer Res Treat. 2023. PMID: 36592232
Clinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer.
van Olmen JP, Schrijver AM, Stokkel MPM, Loo CE, Gunster JLB, Vrancken Peeters MTFD, van Duijnhoven FH, van der Ploeg IMC. van Olmen JP, et al. Among authors: van duijnhoven fh. Breast Cancer Res Treat. 2024 Aug;206(3):585-594. doi: 10.1007/s10549-024-07331-9. Epub 2024 Jun 12. Breast Cancer Res Treat. 2024. PMID: 38864980 Free PMC article.
Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.
van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, Loo CE, Winter-Warnars GAO, Wiersma T, van de Vijver KK, Groen EJ, Blanken-Peeters CFJM, Zonneveld BJGL, Sonke GS, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: van duijnhoven fh, van de vijver kk, van der noordaa mem, van werkhoven ed. Ann Surg Oncol. 2021 Jun;28(6):3243-3253. doi: 10.1245/s10434-020-09273-0. Epub 2020 Dec 2. Ann Surg Oncol. 2021. PMID: 33263830 Free PMC article.
76 results